Regeneron aims for FDA approval of extended dosing for EYLEA HD in AMD and DME, with a decision by April 2025. Pre-filled ...

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and broadening ...

Generic competition is already on the horizon, with Sandoz emerging as a key player. Regeneron’s Eylea, prescribed for age-related macular degeneration and diabetic eye conditions, is another ...

YANTAI, China I April 8, 2025 I On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: ...

South Korea’s pharmaceutical giant Celltrion said Thursday it has received regulatory approvals for three biosimilars in ...

Phil Brooks, a Black American, patented a disposable syringe design on April 9, 1974, contributing to safer healthcare. While not the inventor of the hypodermic syringe, his work added to the history ...

Pykus Therapeutics announced it has completed enrollment in its pilot study, PYK-2101-RD00, evaluating PYK-2101, a focal hydrogel retinal sealant, in patients undergoing surgery for detached retina.

This would be the third indication for aflibercept 8 mg supporting the blockbuster status of Eylea. The submission is based on positive results from the global randomized, double-masked, ...

Celltrion gains Australian approval for three biosimilars in ophthalmology and bone disease Celltrion secures TGA endorsement ...

Cambridge, USA-based Merida Bioscienes, a biotechnology company pioneering a new class of precision therapeutics designed to selectively and durably eliminate the pathogenic antibody drivers of ...

Click to share on Facebook (Opens in new window) Facebook Click to share on X (Opens in new window) X Meth - Photo courtesy of Kira Garmashova on Shutterstock A routine traffic stop in Newport ...

Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the same rare immune diseases as Soliris. Amgen’s Bkemv and Teva/Samsung ...